Cyteir Therapeutics rakes in $29 mln Series B
Cambridge, Massachusetts-based Cyteir Therapeutics, a developer of synthetic lethal therapies that treat cancer and autoimmune disease, has raised $29 million in Series B financing. Venrock led the round with participation from other investors that included Celgene, Lightstone Ventures and DROIA Oncology Ventures.
8 March 2018•4 mins read
